Case Series: COVID-19 in African American Patients With Sarcoidosis.
Case Series: COVID-19 in African American Patients With Sarcoidosis.
复制标题
DOI：
10.3389/fmed.2020.588527
复制
发表时间：
2020
影响因子：
3.9
通讯作者：
Sweiss NJ
中科院分区：
文献类型：
--
作者：
Manansala M;Ascoli C;Alburquerque AG;Perkins D;Mirsaedi M;Finn P;Sweiss NJ
关于结节病合并冠状病毒病19（COVID-19）患者的临床表现和结局的数据很少。在该病例系列中，我们确定了238例结节病患者中的5例，这些患者入组了一项正在进行的纵向观察性研究，他们在研究期间发生了COVID-19，并遵循了他们的临床病程。4名患者完全康复，1名患者在住院期间死亡。我们的初步经验表明，非裔美国人慢性结节病患者接受疾病缓解抗风湿药物（DMARDs）或抗肿瘤坏死因子（TNF）治疗似乎不会增加严重急性呼吸综合征冠状病毒2型呼吸系统或危及生命的并发症的风险（SARS-CoV-2）与一般人群相比，尽管目前，我们主张对这一患者人群保持高度警惕和严格随访。
Data on the clinical presentation and outcomes of sarcoidosis patients with coronavirus disease 19 (COVID-19) are scarce. In this case series, we identified 5 out of 238 sarcoidosis patients who are enrolled in an ongoing longitudinal observational study who developed COVID-19 during the study period and follow their clinical course. Four patients recovered completely, whereas one patient expired during hospital admission. Our preliminary experience suggests that African American patients with chronic sarcoidosis treated with disease-modifying anti-rheumatic drugs (DMARDs) or anti-tumor necrosis factor (TNF) therapy do not seem to be at increased risk of respiratory or life-threatening complications from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compared with the general population, although at the present time, we advocate for maintaining a high level of vigilance and strict follow-up in this patient population.